Newtyn Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Newtyn Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,000,000	Closed	-$1.3M	–	84
2022 Q4	$1.3M	Buy	3,000,000 +1,500,000	+100%	+$487K	0.27%	47
2022 Q3	$420K	Buy	1,500,000 +84,141	+6%	+$28.8K	0.09%	67
2022 Q2	$510K	Buy	+1,415,859	New	+$586K	0.1%	70

Other funds holding SIOX

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Newtyn Management's SIOX Position: Q1 2023 in Review

Newtyn Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 3,000,000 shares — an estimated $1.3M sold.

Newtyn Management first reported a position in SIOX in Q2 2022 and held it in 3 quarters. The position peaked at $1.3M in Q4 2022. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.

Newtyn Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Newtyn Management sold 3,000,000 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $1.3M.
Newtyn Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Newtyn Management's Sio Gene Therapies Inc. Common Stock position peaked at $1.3M in Q4 2022.
4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.

Based on Newtyn Management's 13F filing for Q1 2023, filed 15 May 2023.